Literature DB >> 12010811

B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes.

Rajendra N Damle1, Fabio Ghiotto, Angelo Valetto, Emilia Albesiano, Franco Fais, Xiao-Jie Yan, Cristina P Sison, Steven L Allen, Jonathan Kolitz, Philip Schulman, Vincent P Vinciguerra, Petra Budde, Jurgen Frey, Kanti R Rai, Manlio Ferrarini, Nicholas Chiorazzi.   

Abstract

B-cell chronic lymphocytic leukemia (B-CLL) is considered an accumulative disease of antigen-naive CD5(+) B lymphocytes that circulate in the resting state. However, to evaluate the possibility that B-CLL cells resemble antigen-experienced and activated B cells, we analyzed the expression of markers of cellular activation and differentiation on CD5(+)CD19(+) cells from B-CLL patients and from age-matched healthy donors. The leukemic cells from all B-CLL patients, including those that lack significant numbers of V gene mutations, bear the phenotype of activated B cells based on the overexpression of the activation markers CD23, CD25, CD69, and CD71 and the underexpression of CD22, Fcgamma receptor IIb, CD79b, and immunoglobulin D that are down-regulated by cell triggering and activation. Furthermore, these leukemic cells resemble antigen-experienced lymphocytes in the underexpression of molecules that are down-regulated by cell triggering and in the uniform expression of CD27, an identifier of memory B cells. A comparison of the phenotypes of B-CLL patients with and without immunoglobulin V gene mutations suggests that the 2 subgroups differ both in specific marker expression (CD69, CD71, CD62 L, CD40, CD39, and HLA-DR) and in the time since antigenic stimulation, based on the reciprocal relationship of CD69 and CD71 expression. These findings imply that the leukemic cells from all B-CLL cases (irrespective of V gene mutations) exhibit features of activated and of antigen-experienced B lymphocytes and that the B-CLL cells that differ in immunoglobulin V genotype may have different antigen-encounter histories.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12010811     DOI: 10.1182/blood.v99.11.4087

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  90 in total

1.  Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior.

Authors:  Eva Giné; Antoni Martinez; Neus Villamor; Armando López-Guillermo; Mireia Camos; Daniel Martinez; Jordi Esteve; Xavier Calvo; Ana Muntañola; Pau Abrisqueta; Maria Rozman; Ciril Rozman; Francesc Bosch; Elias Campo; Emili Montserrat
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

Review 2.  Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities.

Authors:  Nicholas Chiorazzi; Manlio Ferrarini
Journal:  Blood       Date:  2010-12-09       Impact factor: 22.113

3.  Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3.

Authors:  George F Widhopf; Craig J Goldberg; Traci L Toy; Laura Z Rassenti; William G Wierda; John C Byrd; Michael J Keating; John G Gribben; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2007-08-03       Impact factor: 22.113

4.  Progressive immunoglobulin gene mutations in chronic lymphocytic leukemia: evidence for antigen-driven intraclonal diversification.

Authors:  Alicia D Volkheimer; J Brice Weinberg; Bethany E Beasley; John F Whitesides; Jon P Gockerman; Joseph O Moore; Garnett Kelsoe; Barbara K Goodman; Marc C Levesque
Journal:  Blood       Date:  2006-11-02       Impact factor: 22.113

5.  Similarities and differences between the light and heavy chain Ig variable region gene repertoires in chronic lymphocytic leukemia.

Authors:  Fabio Ghiotto; Franco Fais; Emilia Albesiano; Cristina Sison; Angelo Valetto; Gianluca Gaidano; Janine Reinhardt; Jonathan E Kolitz; Kanti Rai; Steven L Allen; Manlio Ferrarini; Nicholas Chiorazzi
Journal:  Mol Med       Date:  2006 Nov-Dec       Impact factor: 6.354

6.  The CD38 ectoenzyme family: advances in basic science and clinical practice.

Authors:  Fortunato Morabito; Rajendra N Damle; Silvia Deaglio; Michael Keating; Manlio Ferrarini; Nicholas Chiorazzi
Journal:  Mol Med       Date:  2006 Nov-Dec       Impact factor: 6.354

Review 7.  Fc receptors and their role in immune regulation and autoimmunity.

Authors:  Toshiyuki Takai
Journal:  J Clin Immunol       Date:  2005-01       Impact factor: 8.317

8.  Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA.

Authors:  Charles C Chu; Rosa Catera; Katerina Hatzi; Xiao-Jie Yan; Lu Zhang; Xiao Bo Wang; Henry M Fales; Steven L Allen; Jonathan E Kolitz; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

Review 9.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

Review 10.  Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia.

Authors:  Clive S Zent; Neil E Kay
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.